Upstream Bio Reports Positive Top-Line Results from the Phase 2 VIBRANT Trial of Verekitug for the Treatment of Chronic Rhinosinusitis with Nasal Polyps (CRSwNP)
1. VIBRANT trial showed verekitug met primary endpoint with significant improvement. 2. Key secondary endpoints also demonstrated notable positive effects. 3. Verekitug had a favorable safety profile, with no serious adverse events. 4. Management sees potential for verekitug to redefine CRSwNP treatment. 5. Further data anticipated for severe asthma indication soon.